These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10689256)

  • 1. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
    O'Brien BJ; Willan A; Blackhouse G; Goeree R; Cohen M; Goodman S
    Am Heart J; 2000 Mar; 139(3):423-9. PubMed ID: 10689256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.
    Brosa M; Rubio-Terrés C; Farr I; Nadipelli V; Froufe J
    Pharmacoeconomics; 2002; 20(14):979-87. PubMed ID: 12403638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
    Mark DB; Cowper PA; Berkowitz SD; Davidson-Ray L; DeLong ER; Turpie AG; Califf RM; Weatherley B; Cohen M
    Circulation; 1998 May; 97(17):1702-7. PubMed ID: 9591764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.
    Balen RM; Marra CA; Zed PJ; Cohen M; Frighetto L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):533-42. PubMed ID: 10662478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
    Orlewska E; Budaj A; Tereszkowski-Kaminski D
    Pharmacoeconomics; 2003; 21(10):737-48. PubMed ID: 12828495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
    Mark D
    Can J Cardiol; 1998 Aug; 14 Suppl E():24E-27E. PubMed ID: 9779030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease.
    Nicholson T; McGuire A; Milne R
    BMC Cardiovasc Disord; 2001; 1():2. PubMed ID: 11701090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial.
    Detournay B; Huet X; Fagnani F; Montalescot G
    Pharmacoeconomics; 2000 Jul; 18(1):83-9. PubMed ID: 11010607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital.
    Ahmad A; Patel I; Asani H; Jagadeesan M; Parimalakrishnan S; Selvamuthukumaran S
    Indian J Pharmacol; 2015; 47(1):90-4. PubMed ID: 25821318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors easily obtained at presentation predict resource utilization in unstable angina.
    Calvin JE; Klein LW; VandenBerg BJ; Meyer P; Ramirez-Morgen LM; Parrillo JE
    Am Heart J; 1998 Sep; 136(3):373-81. PubMed ID: 9736126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
    Spyropoulos AC; Hurley JS; Ciesla GN; de Lissovoy G
    Chest; 2002 Jul; 122(1):108-14. PubMed ID: 12114345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B.
    Fox KA
    Semin Hematol; 2001 Apr; 38(2 Suppl 5):67-74. PubMed ID: 11449345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
    J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.